Vitrolife AB (VITR) AI Stock Analysis

• Market Cap: kr19.11B
• Dividend Yield: 7.55%
• Average Volume (3M): 134.59K
• Price to Earnings (P/E): 38.4
• Beta (1Y): 0.72
• Revenue Growth: 3.17%
• EPS Growth: N/A
• Country: SE
• Employees: 1,150
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): 0.74
• Shares Outstanding: 135,447,190
• 10 Day Avg. Volume: 91,327
• 30 Day Avg. Volume: 134,588
• PEG Ratio: -31.67
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 45.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: kr169.00 ▲(19.77%Upside)

Vitrolife AB's overall stock score is primarily supported by its solid financial performance, indicating stability and strong cash management. However, the technical analysis reflects a lack of clear market momentum, and the current valuation suggests that the stock is priced at a premium, which might deter new investors. While financial fundamentals are strong, the lack of growth signals and overvaluation pose potential risks.

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Vitrolife AB generates revenue primarily through the sale of its IVF-related products and services. The company's revenue model is centered around its comprehensive portfolio of products that cater to various stages of the IVF process, such as culture media, embryo assessment tools, and cryopreservation solutions. Additionally, Vitrolife offers time-lapse technology and other medical devices that support fertility clinics in optimizing treatment outcomes. Key revenue streams include direct sales to fertility clinics and laboratories, as well as distribution partnerships that extend its market reach. Vitrolife's financial performance is bolstered by its strategic emphasis on research and development, enabling the company to introduce innovative products and maintain a competitive edge in the rapidly evolving field of assisted reproduction.

Vitrolife AB Financial Statement Overview

Summary

Vitrolife AB maintains a strong financial position with healthy profitability margins, low leverage, and efficient cash flow management. While growth in revenue and net income has stagnated, the company's stability and cash generation capabilities provide a solid foundation for future growth opportunities.

Income Statement

Vitrolife AB shows strong profitability with a consistent Gross Profit Margin of around 57% in the TTM period. The EBIT and EBITDA margins are healthy, indicating efficient cost management. However, revenue growth is stagnant, and net income has slightly declined in the TTM compared to the previous annual report, signaling potential concerns in sustaining growth momentum.

Balance Sheet

The company's balance sheet reveals a strong equity position with a high Equity Ratio of approximately 79% in the TTM. The Debt-to-Equity ratio is manageable at 0.15, reflecting low leverage and financial stability. However, Return on Equity has slightly declined in the TTM period, suggesting room for improved profitability on equity.

Cash Flow

Vitrolife AB demonstrates robust cash management with a positive Free Cash Flow and a solid Operating Cash Flow to Net Income Ratio of 1.56 in the TTM period. Despite a decrease in Free Cash Flow due to reduced Operating Cash Flow, the company's cash generation capabilities remain strong, supporting its financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.61B	3.61B	3.51B	3.23B	1.68B	1.25B
Gross Profit	2.08B	2.14B	1.98B	1.78B	1.05B	767.67M
EBITDA	980.00M	783.00M	-3.19B	993.00M	579.60M	438.65M
Net Income	498.00M	513.00M	-3.85B	394.00M	341.00M	286.85M
Balance Sheet
Total Assets	16.63B	17.45B	16.33B	20.55B	19.43B	2.31B
Cash, Cash Equivalents and Short-Term Investments	1.05B	1.14B	861.00M	578.00M	630.09M	973.57M
Total Debt	1.95B	2.09B	2.09B	2.23B	2.48B	62.40M
Total Liabilities	3.50B	3.81B	3.61B	3.81B	4.09B	288.07M
Stockholders Equity	13.13B	13.64B	12.72B	16.74B	15.32B	2.01B
Cash Flow
Free Cash Flow	694.00M	907.00M	638.00M	549.00M	321.86M	336.36M
Operating Cash Flow	779.00M	907.00M	757.00M	636.00M	384.31M	356.45M
Investing Cash Flow	-388.00M	-377.00M	-124.00M	-144.00M	-6.52B	-20.22M
Financing Cash Flow	-222.00M	-286.00M	-300.00M	-582.00M	5.75B	-26.61M

Vitrolife AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 141.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Neutral. The current price of 141.1 is below the 20-day moving average (MA) of 146.15, below the 50-day MA of 150.88, and below the 200-day MA of 196.36, indicating a bearish trend. The MACD of -4.61 indicates Positive momentum. The RSI at 42.27 is Neutral, neither overbought nor oversold. The STOCH value of 37.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	65 Neutral	kr19.11B	38.37	3.79%	7.55%	3.17%	―
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
0O5H		kr18.64B	78.49	2.43%	4.92%	―	―
ADDLF		$2.43B	83.87	5.83%	3.77%	―	―
BOEUF		$1.97B	172.71	18.01%	―	―	―
XVIPF		$962.63M	72.99	6.57%	―	―	―
B9A		€1.45B	17.30	60.96%	―	―	―

Vitrolife AB Corporate Events

Vitrolife AB Invests in AutoIVF to Enhance IVF Accessibility

Vitrolife AB has become a leading investor in AutoIVF, an early-stage MedTech company, to enhance the accessibility and affordability of IVF treatments. This strategic investment supports Vitrolife’s goal of automating the IVF process and building a comprehensive platform for fertility care, potentially impacting the reproductive health industry by decentralizing egg retrieval and improving service efficiency.